Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China

Penghui Yang; Yibo Ding; Zhe Xu; Rui Pu; Ping Li; Jin Yan; Jiluo Liu; Fanping Meng; Lei Huang; Lei Shi; Tianjun Jiang; Enqiang Qin; Min Zhao; Dawei Zhang; Peng Zhao; Lingxiang Yu; Zhaohai Wang; Zhixian Hong; Zhaohui Xiao; Qing Xi; Dexi Zhao; Peng Yu; Caizhong Zhu; Zhu Chen; Shaogeng Zhang; Junsheng Ji; Guangwen Cao; Fusheng Wang

Before 2002, 4 kinds of coronaviruses (CoVs, namely HCoV 229E, NL63, OC43, and HKU1) were known to infect humans, causing 10%-30% mild upper respiratory infection in adults, occasionally severe pneumonia in elders, infants, and immunodeficient persons. 1 Epidemiologic data indicated clear evidence of person-to-person transmission, and the transmission led to nosocomial infection. [5] [6] [7] The case number increased quickly in Wuhan and posed a large casualty. Up to February 24, 2020, a total of 46607 confirmed cases had been identified in Wuhan, with an estimated case fatality of 4.26% (1987 deaths). SARS-CoV-2 rapidly spread to other parts of Hubei province, other parts of China, and 29 countries, resulting in 17680 cases and 508 deaths (estimated fatality: 2.87%), 12975 cases and 100 deaths (0.77%), and 2105 cases and 24 deaths (1.14%), respectively (up to February 24, 2020). The transmissibility of SARS-CoV-2 is higher and the fatality is lower compared to SARS-CoV, although the two CoVs share the receptor-human angiotensin converting enzyme II (ACE2). [8] [9] [10] The etiological, epidemiological, and clinical characteristics of COVID-19 epidemic in Wuhan have been investigated since the disease outbreak. 3, [5] [6] [7] [10] [11] [12] [13] [14] The occurrences of COVID-19 cases outside Wuhan were reported. [15] [16] [17] [18] [19] The difference in the fatality rates . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.